On December 28, 2024, a new generation of intelligent bone regeneration technology was approved by the FDA, and OSSIO received an additional funding of 200 million yuan. With the aging population and technological innovation, orthopedic implant medical devices face a broad development prospect. The global market size is expected to reach $48 billion in 2024.
OSSIO is committed to becoming the gold standard in the field of orthopedic fixation, promoting natural bone healing, and reducing complications and pain. Below is the formatted content for a WordPress blog post:
—
**Innovating Fixation with Intelligent Bone Regeneration Technology**
OSSIO’s cutting-edge OSSIOfiber™ platform ushers in a new category of fixation – “bio-integratives.” This next-generation intelligent bone regeneration technology achieves high mechanical strength with no residual material left after recovery, thanks to its innovative composition and internal structure.
**Hybrid Integration Mechanism for Unparalleled Strength and Healing**
OSSIOfiber implants are composed of approximately 50% continuous reinforcing natural mineral fibers and 50% biodegradable polymers. This hybrid integration mechanism delivers integration with the native anatomical structure, featuring:
– High mineral content that supports high mechanical strength and gradual bone integration.
– A balanced pH environment that fosters a healthy milieu for bone healing.
– Interconnected pores that progressively allow fluid flow and the removal of degradation by-products.
**FDA Approval and Customizable Internal Structures**
The uniqueness of OSSIO’s enhanced bio-integration technology lies in the ability to adjust the internal structure of each implant to achieve optimal biomechanical characteristics. Currently, the OSSIOfiber bio-integration fixation technology has received FDA approval.
**Product Line Overview**
The company has developed a suite of products based on OSSIOfiber technology, including suture anchors, compression nails, and compression screws, all boasting strong initial tensile strength and sustained durability.
**Financing Situation**
On December 2, 2024, OSSIO completed a new round of financing, raising $27.6 million, primarily aimed at accelerating commercialization efforts.
**Development of China’s Orthopedic Medical Device Industry**
China’s orthopedic medical device industry is growing rapidly, with multiple bone repair materials approved for market. The market is entering a phase of expansion and import substitution. Here’s a glimpse:
– Companies like Hangzhou Jiuyuan Gene and Yantai Zhenghai Bio are gradually changing the market landscape.
– Products like Lixin Science’s GaiaBone® have received FDA approval for market launch.
**Conclusion**
This article introduces OSSIO’s new generation of intelligent bone regeneration technology, its application in the field of orthopedic implant medical devices, and its financing situation. It also offers an overview of the development of China’s orthopedic medical device industry.
—
Below is the content formatted for WordPress:
On December 28, 2024, a new generation of intelligent bone regeneration technology was approved by the FDA, and OSSIO received an additional funding of 200 million yuan. With the aging population and technological innovation, orthopedic implant medical devices face a broad development prospect. The global market size is expected to reach $48 billion in 2024.
OSSIO’s cutting-edge OSSIOfiber™ platform ushers in a new category of fixation – “bio-integratives.” This hybrid integration mechanism delivers unparalleled strength and healing. OSSIOfiber implants are now FDA approved, and the internal structures are customizable.
The company has developed a suite of products, and recent financing will accelerate commercialization efforts. Meanwhile, China’s orthopedic medical device industry is witnessing rapid growth and innovation.
Companies like Hangzhou Jiuyuan Gene and Yantai Zhenghai Bio are leading the change, with products like Lixin Science’s GaiaBone® gaining international recognition.
This marks a significant milestone in the journey of OSSIO and the broader orthopedic medical device industry.
